Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group - Université Clermont Auvergne Access content directly
Journal Articles American Journal of Hematology Year : 2017

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group

Domains

Hematology

Dates and versions

hal-01653723 , version 1 (01-12-2017)

Identifiers

Cite

Sophie Michallet, Arnaud Campidelli, Helene Lequeu, Marie-Sarah Dilhuydy, Olivier Tournilhac, et al.. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. American Journal of Hematology, 2017, 92 (6), pp.E105 - E107. ⟨10.1002/ajh.24715⟩. ⟨hal-01653723⟩
231 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More